Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best Choices

• Tipo: Outras Publicações
• Data: 2023

Autores

Roque, K (Autor) Outra; Ruiz, R (Autor) Outra; Mas, L (Autor) Outra; Daniel Pozza (Autor) FMUP; Vancini, M (Autor) Outra; Silva, JA (Autor) Outra; De Mello, RA (Autor) Outra

Outras Informações

ID Authenticus: P-00Z-GV7

DOI: 10.20944/preprints202307.1242.v1

Abstract (EN): <jats:p>The advent of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), improving the prognosis of this disease and becoming a key part of the treatment, especially in the population without an oncogenic driver mutation. Two different groups of immune checkpoint inhibitors (ICIs) are used in lung cancer: Anti- Cytotoxic T-lymphocyte antigen-4 (Anti-CTLA 4) and Anti- T-cell receptor programmed cell death-1 or its ligand (Anti-PD-1 and Anti PD-L1). Here in, we review an uptodate on the use of immunotherapy for advanced NSCLC.</jats:p>

Idioma: Inglês

Tipo (Avaliação Docente): Científica